Skip to main content
Molecular & Cellular Proteomics : MCP logoLink to Molecular & Cellular Proteomics : MCP
. 2014 Aug 5;13(11):3138–3151. doi: 10.1074/mcp.M113.033217

Down-regulation of Ras-related Protein Rab 5C-dependent Endocytosis and Glycolysis in Cisplatin-resistant Ovarian Cancer Cell Lines*

Lixu Jin §,**, Yi Huo ‡,**, Zhiguo Zheng , Xiaoyong Jiang , Haiyun Deng §, Yuling Chen , Qingquan Lian §, Renshan Ge §, Haiteng Deng ‡,
PMCID: PMC4223497  PMID: 25096996

Abstract

Drug resistance poses a major challenge to ovarian cancer treatment. Understanding mechanisms of drug resistance is important for finding new therapeutic targets. In the present work, a cisplatin-resistant ovarian cancer cell line A2780-DR was established with a resistance index of 6.64. The cellular accumulation of cisplatin was significantly reduced in A2780-DR cells as compared with A2780 cells consistent with the general character of drug resistance. Quantitative proteomic analysis identified 340 differentially expressed proteins between A2780 and A2780-DR cells, which involve in diverse cellular processes, including metabolic process, cellular component biogenesis, cellular processes, and stress responses. Expression levels of Ras-related proteins Rab 5C and Rab 11B in A2780-DR cells were lower than those in A2780 cells as confirmed by real-time quantitative PCR and Western blotting. The short hairpin (sh)RNA-mediated knockdown of Rab 5C in A2780 cells resulted in markedly increased resistance to cisplatin whereas overexpression of Rab 5C in A2780-DR cells increases sensitivity to cisplatin, demonstrating that Rab 5C-dependent endocytosis plays an important role in cisplatin resistance. Our results also showed that expressions of glycolytic enzymes pyruvate kinase, glucose-6-phosphate isomerase, fructose-bisphosphate aldolase, lactate dehydrogenase, and phosphoglycerate kinase 1 were down-regulated in drug resistant cells, indicating drug resistance in ovarian cancer is directly associated with a decrease in glycolysis. Furthermore, it was found that glutathione reductase were up-regulated in A2780-DR, whereas vimentin, HSP90, and Annexin A1 and A2 were down-regulated. Taken together, our results suggest that drug resistance in ovarian cancer cell line A2780 is caused by multifactorial traits, including the down-regulation of Rab 5C-dependent endocytosis of cisplatin, glycolytic enzymes, and vimentin, and up-regulation of antioxidant proteins, suggesting Rab 5C is a potential target for treatment of drug-resistant ovarian cancer. This constitutes a further step toward a comprehensive understanding of drug resistance in ovarian cancer.


Ovarian cancer is the major cause of death in women with gynecological cancer. Early diagnosis of ovarian cancer is difficult, while its progression is fast. The standard treatment is surgical removal followed by platinum-taxane chemotherapy. However, the efficacy of the traditional surgery and chemotherapy is rather compromised and platinum resistant cancer recurs in ∼25% of patients within six months, and the overall five-year survival rate is about 31% (13). Virtually no efficient second line treatment is available. In order to increase survival rates from ovarian cancer and enhance patients' quality of life, new therapeutic targets are urgently required, necessitating a deeper understanding of molecular mechanisms of drug resistance.

Mechanisms of drug-resistance in ovarian cancer have been extensively studied over the last 30 years. Earlier studies have found that multiple factors are linked to drug resistance in human ovarian cancer including reduced intracellular drug accumulation, intracellular cisplatin inactivation, and increased DNA repair (4). Reduced cellular drug accumulation is mediated by the copper transporter-1 responsible for the influx of cisplatin (59) and MDR1, which encodes an integral membrane protein named P-glycoprotein for the active efflux of platinum drugs. Up-regulation of MDR1 has been observed in cisplatin-treated ovarian cancer cells although cisplatin is not a substrate of P-glycoprotein (1013). A fraction of intracellular cisplatin can be converted into cisplatin-thiol conjugates by glutathione-S-transferase (GST) π, leading to inactivation of cisplatin. Up-regulation of both GSTπ and γ-glutamylcysteine synthetase has been associated with cisplatin resistance in ovarian, cervical and lung cancer cell lines (1418). Binding of cisplatin to DNA leads to intrastrand or interstrand cross-links that alter the structure of the DNA molecule causing DNA damage. It has been amply documented that pathways for recognition and repair of damaged DNA are up-regulated in drug-resistant cancer cells (1926). Furthermore, the secondary mutations have been identified, which restore the wild-type BRCA2 reading frame enhancing the acquired resistance to platinum-based chemotherapy (24). Alternations in other signaling pathways have also been found in drug resistant ovarian cancer (2729). For example, DNA-PK phosphorylates RAC-alpha serine/threonine-protein kinase (AKT) and inhibits cisplatin-mediated apoptosis (28); and silencing of HDAC4 increases acetyl-STAT1 levels to prevent platinum-induced STAT1 activation and restore cisplatin sensitivity (29).

Proteomics is playing an increasingly important role in identifying differentially expressed proteins between drug-resistant and drug sensitive ovarian cancer cells (3035). An earlier study has identified 57 differentially expressed proteins in human ovarian cancer cells and their platinum-resistant sublines, including annexin A3, destrin, cofilin 1, Glutathione-S-transferase omega 1, and cytosolic NADP+-dependent isocitrate dehydrogenase using 2D gel electrophoresis (30). Employing a similar 2D gel electrophoresis approach, changes in protein expressions of capsid glycoprotein, fructose-bisphosphate aldolase C, heterogeneous nuclear ribonucleoproteins A2/B1, putative RNA-binding protein 3, Ran-specific GTPase-activating protein, ubiquitin carboxyl-terminal hydrolase isozyme L1, stathmin, ATPSH protein, chromobox protein homolog3, and phosphoglycerate kinase 1 (PGK)1 were found in A2780 and drug-resistant A2780 cells (32). It is worth mentioning that ALDO and PGK are glycolytic enzymes, indicating that glycolysis plays a role in drug resistance. Studies have demonstrated that resistance to platinum drugs in ovarian cancer cells is linked to mitochondrial dysfunctions in oxidative phosphorylation and energy production (3640). Mitochondrial proteomic analysis of drug-resistant cells has shown that five mitochondrial proteins (ATP-a, PRDX3, PHB, ETF, and ALDH) that participate in the electron transport respiratory chain are down-regulated in drug-resistant cell lines (41). PRDX3 is involved in redox regulation of the cell to protect radical-sensitive enzymes from oxidative damage. However, it is not clear how down-regulation of PRDX3 is associated with drug-resistance. A more recent study showed that activated leukocyte cell adhesion molecule (ALCA) and A kinase anchoring protein 12 (AKAP12) are elevated in drug-resistant A2780-CP20 cells by quantifying the mitochondrial proteins (42). Despite these efforts, the drug-resistance mechanisms are not yet well understood.

In this work, we established and characterized a drug-resistant cell line A2780-DR from A2780 cells. We employed a quantitative proteomic method to identify the differentially expressed proteins between A2780 and A2780-DR cells. Expression changes of selected proteins were confirmed by qPCR and Western blotting. We also used shRNA silencing to explore functions of Rab 5C and Rab 11B proteins in drug resistance. Our data indicate that the differentially expressed proteins participate in a variety of cellular processes and enhance our understanding of the mechanisms of drug resistance in ovarian cancer cells.

MATERIALS AND METHODS

Chemicals and Reagents

Dulbecco's Modified Eagle Medium (DMEM), fetal bovine serum, and penicillin-streptomycin were purchased from Wistent (Saint-Jean-Baptiste, CA). Dithiothreitol (DTT) was purchased from Calbiochem (San Diego, CA). The A2780 cell line was obtained from the Tumor Cell Bank of the Chinese Academy of Medical Sciences (Beijing, China). Sequencing grade modified trypsin was purchased from Promega (Fitchburg, WI). The propidium iodide staining kit was purchased from Solarbio (Beijing, China). The TMT labeling kit was purchased from Thermo-Pierce Biotechnology (Rockford, IL).

Cell Culture and Establishment of Cisplatin Resistant Subline

The human epithelial ovarian cancer cell line A2780 cells were maintained in DMEM media supplemented with 10% fetal bovine serum and penicillin (100 U/ml)–streptomycin (100 mg/ml) at 37 °C with 5% CO2. Cells were grown as monolayer cultures in 10 cm tissue culture plate and passaged when they had reached about 90% confluence. A monoclonal strain was separated by flow cytometry and further cultured to obtain A2780 cisplatin resistant strain (A2780-DR) by incubation with stepwise increasing cisplatin concentrations. Backups of all cells were stored with 10% DMSO. Every 20 passages, a new backup of cells was thawed to ascertain that resistance mechanisms were unchanged during long term cultivation. The relative cisplatin resistance was determined by cell viability assay.

Cell Cytotoxicity Assay

Effects of cisplatin on cell proliferation in A2780 and A2780-DR were analyzed with the Cell Counting Kit-8 (CCK-8) from Dojindo (Japan). A2780 and A2780-DR cells (8 × 103 each) were seeded into wells in 96-well cell culture microplates and incubated for 16 h prior to cisplatin treatment. Cells were then treated with cisplatin at different concentrations (0, 20, 40, 80, 160, and 320 μm) in triplicates for 24 h. The CCK8 reagent was added to treated cells and incubated at 37 °C for 2 h. Optical density (OD) was measured at 450 nm with a microplate reader (Bio-Rad, Hercules). Cell viability was calculated as the percentage of variable cells compared with untreated cells. The experiment was repeated three times and the IC50 was calculated by SPSS13.0 (SPSS Inc., Chicago, IL,). The lower the IC50 value, the higher the potency against cell proliferation.

Sample Preparation and Quantitative Proteomic Analysis

About 6 × 105 cells were lysed using RIPA lysis buffer (Solabio, Beijing, China), and protein concentrations were measured using the BCA method. Equal amount of proteins from untreated- and treated-samples (about 30 μg) were separated by 1D SDS-PAGE, respectively. The gel bands of interest were excised from the gel, reduced with 25 mm of dithiotreitol, and alkylated with 55 mm iodoacetamide. In gel digestion was then carried out with sequencing grade modified trypsin in 50 mm ammonium bicarbonate at 37 °C overnight. The peptides were extracted twice with 0.1% trifluoroacetic acid in 50% acetonitrile aqueous solution for 30 min. Extracts were then centrifuged in a speedvac to reduce the volume. Tryptic peptides were redissolved in 50 μl 200 mm Tetraethylammonium Bromide (TEAB), and 2 μl TMTsixplex labeling reagent was added to each sample according to the manufacture's instruction. The reaction was incubated for 1 h at room temperature. Then, 0.5 μl of 5% hydroxylamine (pH 9–10) was added to the reaction mixture and incubated for 15 min to quench the reaction. Equal amount of proteins from A2780 and A2780-DR cells were combined and analyzed by LC-MS/MS.

For LC-MS/MS analysis, the TMT-labeled peptides were separated by a 65 min gradient elution at a flow rate 0.250 μl/min with a Thermo-Dionex Ultimate 3000 HPLC system, which was directly interfaced with a Thermo Scientific Q Exactive mass spectrometer. The analytical column was a home-made fused silica capillary column (75 μm ID, 150 mm length; Upchurch, Oak Harbor, WA) packed with C-18 resin (300 Å, 5 μm, Varian, Lexington, MA). Mobile phase A consisted of 0.1% formic acid, and mobile phase B consisted of 100% acetonitrile and 0.1% formic acid. The Q Exactive mass spectrometer was operated in the data-dependent acquisition mode using Xcalibur 2.1.2 software and there was a single full-scan mass spectrum in the orbitrap (400–1800 m/z, 60,000 resolution) followed by 10 data-dependent MS/MS scans at 27% normalized collision energy.

The MS/MS spectra from each LC-MS/MS run were searched against the human.fasta from UniProt (release date of March 19, 2014; 68406 entries) using an in-house Proteome Discoverer (Version PD1.4, Thermo-Fisher Scientific). The search criteria were as follows: full tryptic specificity was required; one missed cleavage was allowed; carbamidomethylation (C) and TMT sixplex (K and N-terminal) were set as the fixed modifications; the oxidation (M) was set as the variable modification; precursor ion mass tolerances were set at 10 ppm for all MS acquired in an orbitrap mass analyzer; and the fragment ion mass tolerance was set at 20 mmu for all MS2 spectra acquired. The peptide false discovery rate was calculated using Percolator provided by PD. When the q value was smaller than 1%, the peptide spectrum match was considered to be correct. False discovery was determined based on peptide spectrum match when searched against the reverse, decoy database. Peptides only assigned to a given protein group were considered as unique. The false discovery rate was also set to 0.01 for protein identifications. Relative protein quantification was performed using Proteome Discoverer software (Version 1.4) according to manufacturer's instructions on the six reporter ion intensities per peptide. Quantitation was carried out only for proteins with two or more unique peptide matches. Protein ratios were calculated as the median of all peptide hits belonging to a protein. Quantitative precision was expressed as protein ratio variability. Differentially expressed proteins were further confirmed by qPCR or Western blotting. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the data set identifier PXD001176.

Real-time Quantitative PCR (qPCR)

Cells were harvested 48 h after transfection. Total RNA was extracted by the SV Total RNA Isolation System. cDNA was synthesized from 0.8 μg total RNA using the GoScriptTM Reverse Transcription System. All qPCR was performed using the Roche LightCycler® 480II Detection System with SYBR green incorporation according to the manufacturer's instructions. The primers were either designed by using the Primer Premier 5 software or from Primer Bank (http://pga.mgh.harvard.eduprimerbank/). To prevent amplification of genomic DNA, all target primers span exon-exon junctions. The specific PCR products were confirmed by melting curve analysis. Relative expression was analyzed using the 2−ΔΔCt method. Primer sequences for qPCR are listed in supplemental Table S1.

Western Blotting

Cells were harvested and lysed in RIPA lysis buffer. For shRNA transfected cells, cells were lysed at 72 h after transfection. The supernatants were collected after centrifugation at 14,000 × g for 10 min at 4 °C. Protein concentrations were determined using the BCA protein assay kit. Proteins were separated on a 12% SDS-PAGE gel and transferred onto a polyvinyl diflouride transfer membrane by electroblotting. After blocking with 5% nonfat milk for 2 h at room temperature, the membrane was incubated overnight at 4 °C with 1000× diluted primary antibody, washed with Phosphate Buffered Saline with Tween 20 (PBST) buffer for three times, then incubated with 1000× diluted anti-mouse or anti-rabbit secondary antibody labeled with horseradish peroxidase at room temperature for 2 h. The membrane was further washed with PBST buffer three times and developed using ECL reagents (Engreen, China). β-actin was detected with anti-β-actin antibody as an internal control. BioRad Image Lab software was used to analyze the images.

Determination of Cellular Platinum Accumulation

The cellular platinum accumulation was determined by the method described by Kayoko Minakata (43). Briefly, equal amount of A2780 and A2780-DR cells (about 4 × 106) were collected after 10 μm cisplatin treatment for 24 h. Cell pellets were washed three times with ice-cold PBS. Cell pellet was wet-ashed in 30 μl concentrated HNO3 at 85 °C for 8 h. The pH of wet-ashed solution was adjusted to 3–7 with either 10 m NaOH or 7 m HNO3. 30 μl of 1 m Diethyldithiocarbamate (DDC) was then added to the solution, in which DDC forms a complex with Pt by replacing other bonded ligands. After 3 min, 30 μl of isoamylalcohol was added and mixed for 30 s, and separated by centrifugation. The isoamylalcohol layer was mixed with 30 μl of 1 m oxalic acid for 10 s and centrifuged. A 1 μl aliquot of the isoamylalcohol layer was subjected to electrospray ionization mass spectrometry. Measurements were done in triplicate to determine standard errors of the mean (shown as error bars).

Short Hairpin RNA (ShRNA)-mediated Gene Silencing

The shRNAs against Rab 5C and Rab 11B were designed by the Invitrogen RNAi design tool (http://www.invitrogen.com) and synthesized by Invitrogen, LTD. Nontargeting negative control of shRNA (NCi) was also synthesized. The shRNA sequences are displayed in supplemental Table S2. The oligonucleotides were annealed and inserted into the pll3.7 siRNA expression vector to generate shRNA. The A2780 cells were plated the day before transfection and allowed to grow to 70–80% confluence. The cells were transiently transfected with Rab 5C-shRNA-pll3.7 or Rab 11B-shRNA-pll3.7 respectively with polyethylenimine (PEI) in DMEM. The effectiveness of shRNA in inhibiting Rab 5C and Rab 11B expression was evaluated by real time RT-PCR (48 h after the transfection) and Western blotting analysis (72 h after the transfection). Cells transfected with the plasmid NCi-pll3.7 served as the control.

Overexpression of Rab 5C in A2780-DR Cells

The gene of Rab 5C was cloned from the mRNA by RT-PCR from the Raji cell line, which was then subcloned into eukaryotic plasmid pcDNA3.1B (Invitrogen). The primer sequences are displayed in supplemental Table S2. Briefly, A2780-DR cells were plated the day before transfection and allowed to grow to 70–80% confluence. The cells were transiently transfected with pcDNA3.1 and Rab 5C-pcDNA3.1, respectively. The expression of Rab 5C was examined by Western blotting after 72 h transfection.

Detection of Reactive Oxygen Species (ROS) in A2780 and A2780-DR Cells

The ROS in untreated and azacytidine-treated cells was detected using the Image-iT™ LIVE Green Reactive Oxygen Species Detection Kit (Molecular Probes, Inc. Eugene, OR) following manufacturer's instructions. Briefly, A2780 and A2780-DR cells (2.5 × 105 each) were plated in triplicates in six-well plate the day before the test. After 48 h growth, the cells were collected by centrifugation and washed once with warm HBSS/Ca/Mg. Cells were resuspended with 500 μl of the 25 μm carboxy-H2DCFDA working solution for 25 min at 37 °C, followed by addition of the Hoechst 33342 reagent to the reaction mixture at the final concentration of 1.0 μm and incubation for 5 min. The final products were gently washed with 1 ml HBSS/Ca/Mg immediately followed by imaging with Zeiss 710 Confocal Microscopy.

RESULTS

Characterization of the Drug-resistant A2780 Cell Line

The drug-resistant cell line A2780-DR was established by the stepwise selection of A2780 cells cultured in growth media with increasing drug concentrations over a period of 6 months. To determine the sensitivity of A2780 and A2780-DR cells to cisplatin, cells were treated with different concentrations of cisplatin for 24 h and cell viability was measured by the Cell Counting Kit-8 (CCK-8) assay that allows sensitive colorimetric determination of cell viability and drug-sensitivity. The dose-dependent effects of cisplatin were represented as the percentage of viable cells as compared with untreated cells (Fig. 1A). When cells were treated with 80 μm cisplatin for 24h, percentages of viable cells were 40 and 100% for A2780 and A2780-DR cells, respectively. The inhibitory concentration 50% (IC50) and resistance index (RI) values of the two cell lines are displayed in Table I, indicating that A2780-DR is cisplatin resistant. The resistant phenotype is stable as the values of IC50 and RI have no significant changes over a period of 4 months in drug-free medium.

Fig. 1.

Fig. 1.

A, Cell cytotoxicity assays. Percentage of viable A2780-DR and A2780 cells treated with cisplatin at different concentrations for 24 h determined by using CCK-8 assay. Results are expressed as the mean of three experiments with p value <0.001; B, accumulation of cisplatin in 10 μm cisplatin treated A2780 and A2780-DR cells for 24 h as determined by electrospray ionization mass spectrometry. *** p < 0.001.

Table I. IC50 and Resistance Index of A2780-related cells to cisplatin treatment.
IC50 (μm) RI
A2780 61.0 ± 2.3 1
A2780-DR 404.9 ± 15.1 6.6
EV-A2780a 54.6 ± 5.0 1
ShRNA(Rab5C)-A2780 103.3 ± 6.2 1.9
EV-A2780 45.1 ± 2.7 1
ShRNA(Rab11B)-A2780 62.7 ± 3.2 1.4

a Empty vector transfected cells.

We also analyzed the total cellular Pt accumulation in sensitive and resistant cells following exposure to 10 μm cisplatin treatment for 24 h. The relative cisplatin concentrations were displayed in Fig. 1B as determined by mass spectrometry. After treatment with cisplatin, total intracellular Pt in A2780-DR is about one third of that in the parent cell line A2780, indicating significant reduction of cisplatin accumulation in drug-resistant cells.

Proteomic Analysis of A2780 and A2780-DR Cells

Next, proteomic analysis was carried out on A2780 and A2780-DR cells. Equal amounts of proteins from A2780 and A2780-DR cells were loaded and separated by 1D SDS-PAGE (Fig. 2). Differentially expressed proteins were identified and quantified using TMT-labeling. The experiments were repeated three times and ∼1900 proteins were identified for each cell line. The false-positive rate was set to be less than 1%. Based on TMT ratios (>2.0 or <0.6) in proteins that have two or more unique peptides, 340 proteins were found to be differentially expressed between A2780 and A2780-DR cells, of which 268 proteins are down-regulated and 72 up-regulated (Table II and III). The major protein in band 7 that was down-regulated in A2780-DR was identified as vimentin. HSP90α and HSP90β in band 4 were also down-regulated in the drug-resistant cells (Fig. 2). In order to understand the biological relevance of the identified proteins, Gene Ontology (GO) was used to categorize the differentially expressed proteins according to their molecular functions and biological processes. The annotations of gene lists are summarized via a pie plot using the PANTHER bioinformatics platform (http://www.pantherdb.org/) as shown in Fig. 3. Three hundred and thirty nine proteins were classified into several significant groups of biological processes including metabolic processes, cellular processes, cellular compartment organization, and apoptosis.

Fig. 2.

Fig. 2.

1D SDS-PAGE gel image of A2780 and A2780-DR cells. Lane 1, molecular weight markers; Lane 2, proteins from A2780 cells; Lane 3, proteins from A2780-DR cells; and bands excised from the gel with differentially expressed proteins are labeled with numeric numbers.

Table II. Up-regulated proteins in cisplatin resistant cells.
Accession Description Score Coverage (%) Unique peptides A2780-DR/A2780
E9PM69 26S protease regulatory subunit 6A 17 15 5 3.5
O00231 26S proteasome non-ATPase regulatory subunit 11 18 16 6 5.1
P36578 60S ribosomal protein L4 77 30 12 5.1
B4DQJ8 6-phosphogluconate dehydrogenase, decarboxylating 23 24 8 3.7
G3V4F2 Acyl-coenzyme A thioesterase 1 14 14 4 3.6
P30520 Adenylosuccinatesynthetaseisozyme 2 16 13 4 4.4
P30837 Aldehyde dehydrogenase X, mitochondrial 22 18 6 6.3
F8VS02 Alpha-aminoadipicsemialdehyde dehydrogenase 17 17 7 6.2
P06733 Alpha-enolase 217 53 16 4.8
B4DT77 Annexin 23 12 4 2.4
P25705 ATP synthase subunit alpha, mitochondrial 136 45 19 6.8
P06576 ATP synthase subunit beta, mitochondrial 199 52 20 5.4
R4GMX5 Basigin (Fragment) 11 36 3 4.7
H3BS10 Beta-hexosaminidase 17 8 3 2.3
Q13895 Bystin 10 6 3 4.2
P10644 cAMP-dependent protein kinase type I-alpha regulatory subunit 13 18 6 3.4
C9JP16 Cartilage-associated protein 12 12 5 5.3
P31930 Cytochrome b-c1 complex subunit 1, mitochondrial 27 17 6 5.7
B7Z5W8 Dihydrolipoyllysine-residue succinyltransferase component 11 11 4 6.4
P39656 Dolichyl-diphosphooligosaccharide–protein glycosyltransferase 48 kDa subunit 46 21 9 5.5
Q05639 Elongation factor 1-alpha 2 256 20 2 3.1
P26641 Elongation factor 1-gamma 62 32 13 4.7
P49411 Elongation factor Tu, mitochondrial 88 27 11 4.5
F5H0C8 Enolase 52 11 2 4.1
P07099 Epoxide hydrolase 1 42 24 11 5.3
Q96CG1 ETF1 protein 13 6 2 2.7
P38919 Eukaryotic initiation factor 4A-III 31 21 6 4.7
H7BZU1 Eukaryotic translation initiation factor 2 subunit 3 (Fragment) 10 11 2 3.9
O00303 Eukaryotic translation initiation factor 3 subunit F 17 17 5 3.6
J3KNT0 Fascin 18 23 9 4.1
J3QRD1 Fatty aldehyde dehydrogenase 27 14 5 8.1
P39748 Flap endonuclease 1 12 8 3 4.6
P00367 Glutamate dehydrogenase 1, mitochondrial 22 18 8 5.9
P52597 Heterogeneous nuclear ribonucleoprotein F 47 14 2 3.6
P31943 Heterogeneous nuclear ribonucleoprotein H 94 33 5 4.5
P55795 Heterogeneous nuclear ribonucleoprotein H2 51 18 2 4.3
B3KWE1 Histidine–tRNA ligase, cytoplasmic 15 6 3 3.9
P0C0S5 Histone H2A.Z 283 31 2 2.1
H7C3I1 Hsc70-interacting protein (Fragment) 17 23 3 6.6
Q6YN16 Hydroxysteroid dehydrogenase-like protein 2 12 8 3 8.6
P43686-2 Isoform 2 of 26S protease regulatory subunit 6B 15 19 6 6.0
P62195-2 Isoform 2 of 26S protease regulatory subunit 8 15 12 3 3.5
Q16401-2 Isoform 2 of 26S proteasome non-ATPase regulatory subunit 5 35 21 8 4.1
P28838-2 Isoform 2 of Cytosol aminopeptidase 26 19 8 6.9
Q9H0S4-2 Isoform 2 of Probable ATP-dependent RNA helicase DDX47 12 10 3 7.3
P35659-2 Isoform 2 of Protein DEK 17 11 4 4.3
P50395-2 Isoform 2 of Rab GDP dissociation inhibitor beta 33 26 5 4.9
Q8NBS9-2 Isoform 2 of Thioredoxin domain-containing protein 5 47 39 11 4.3
O14773-2 Isoform 2 of Tripeptidyl-peptidase 1 10 9 2 4.9
P34897-3 Isoform 3 of Serine hydroxymethyltransferase, mitochondrial 37 20 9 6.5
P00390-5 Isoform 4 of Glutathione reductase, mitochondrial 25 11 4 6.1
O60664-4 Isoform 4 of Perilipin-3 24 21 6 5.6
P07954-2 Isoform Cytoplasmic of Fumaratehydratase, mitochondrial 28 13 6 5.7
P05455 Lupus La protein 19 16 6 6.3
Q10713 Mitochondrial-processing peptidase subunit alpha 13 10 5 6.3
E7ERZ4 Mitochondrial-processing peptidase subunit beta 11 12 3 5.8
B4DEH8 Polyadenylate-binding protein 2 19 17 3 5.1
Q9UQ80 Proliferation-associated protein 2G4 23 18 7 3.3
B7Z254 Protein disulfide-isomerase A6 95 35 12 7.3
P49257 Protein ERGIC-53 17 7 3 4.8
P18754 Regulator of chromosome condensation 22 19 6 6.2
F8W914 Reticulon 12 12 3 3.6
P00352 Retinal dehydrogenase 1 48 26 11 2.7
P13489 Ribonuclease inhibitor 15 17 5 4.2
Q9Y265 RuvB-like 1 67 31 10 4.6
Q9Y230 RuvB-like 2 36 21 8 3.7
O15269 Serine palmitoyltransferase 1 10 11 4 4.5
P50454 Serpin H1 171 52 19 4.0
Q13838 Spliceosome RNA helicase DDX39B 96 29 3 4.2
P55084 Trifunctional enzyme subunit beta, mitochondrial 21 24 10 7.0
P50552 Vasodilator-stimulated phosphoprotein 10 12 4 4.6
P04004 Vitronectin 11 5 2 2.7
Fig. 3.

Fig. 3.

Functional classification of differentially expressed proteins between A2780 and A2780-DR cells with PANTHER (http://www.pantherdb.org).

Verification of Differentially Expressed Proteins by Western blotting and qPCR

Among differentially expressed proteins (Table III), Ras-related protein Rab 5C and Rab 11B are down-regulated in the drug-resistant cells. Fig. 4 shows a ms/ms spectrum of a peptide ions that match to fragments of a tryptic peptide GVDLQENNPASR from Rab 5C and the insert shows fragments at the low mass range for the TMT-reporter ions, whose ratio indicates that the expression level of Rab 5C is three times higher in A2780 as compared with A2780-DR cells. Down-regulation of Rab 5C and Rab 11B was confirmed by Western blotting (Fig. 5A) and by qPCR analysis (Fig. 5B). Results from analysis of band intensities of Western blot are displayed in supplemental Table S3. Vimentin was the most abundant with the highest spectra count among the differentially expressed proteins and the down-regulation of vimentin was confirmed by Western blotting (Fig. 5A), showing that two bands at 54 and 56 kDa were barely visible for vimentin in A2780-DR cells. Western blotting also confirms that the expression level of PKM2 is down-regulated in A2780-DR cells (Fig. 5A). Proteomic analysis shows that a redox proteins glutathione reductase (GSR) is up-regulated in A2780-DR cells.

Table III. Down-regulated Proteins in cisplatin-resistant cells.
Accession Description Score Coverage (%) Unique Peptides A2780-DR/A2780
Q04917 14-3-3 protein eta 42 26 3 0.3
P61981 14-3-3 protein gamma 57 38 5 0.3
P27348 14-3-3 protein theta 55 27 2 0.3
P63104 14-3-3 protein zeta/delta 75 43 6 0.3
P62191 26S protease regulatory subunit 4 36 22 7 0.6
Q15008 26S proteasome non-ATPase regulatory subunit 6 31 11 4 0.3
R4GMR5 26S proteasome non-ATPase regulatory subunit 8 19 14 5 0.3
P82930 28S ribosomal protein S34, mitochondrial 12 22 5 0.5
P46783 40S ribosomal protein S10 24 23 3 0.3
P62277 40S ribosomal protein S13 22 38 5 0.5
P62269 40S ribosomal protein S18 21 24 4 0.6
P39019 40S ribosomal protein S19 34 48 9 0.6
P62851 40S ribosomal protein S25 26 21 3 0.4
F2Z2S8 40S ribosomal protein S3 15 33 4 0.6
P62701 40S ribosomal protein S4, X isoform 57 32 9 0.3
M0R0F0 40S ribosomal protein S5 (Fragment) 19 27 5 0.5
Q5JR95 40S ribosomal protein S8 21 38 6 0.2
P46781 40S ribosomal protein S9 19 18 4 0.5
C9J9K3 40S ribosomal protein SA (Fragment) 86 36 6 0.2
F8VU65 60S acidic ribosomal protein P0 (Fragment) 26 25 6 0.2
P62906 60S ribosomal protein L10a 20 24 6 0.3
P30050 60S ribosomal protein L12 13 23 3 0.5
P26373 60S ribosomal protein L13 28 27 6 0.3
E7EPB3 60S ribosomal protein L14 29 35 4 0.2
P61313 60S ribosomal protein L15 25 18 5 0.4
G3V203 60S ribosomal protein L18 17 25 4 0.5
P61353 60S ribosomal protein L27 15 21 3 0.6
E9PJD9 60S ribosomal protein L27a 15 34 3 0.5
P49207 60S ribosomal protein L34 18 21 3 0.5
Q02878 60S ribosomal protein L6 23 25 7 0.2
P18124 60S ribosomal protein L7 26 27 6 0.3
O95336 6-phosphogluconolactonase 11 14 3 0.4
P24752 Acetyl-CoA acetyltransferase, mitochondrial 30 22 8 0.4
H0YN26 Acidic leucine-rich nuclear phosphoprotein 32 family member A 15 18 2 0.3
O95433 Activator of 90 kDa heat shock protein ATPase homolog 1 19 18 5 0.3
Q01518 Adenylyl cyclase-associated protein 1 73 31 14 0.5
P12235 ADP/ATP translocase 1 128 32 2 0.3
P05141 ADP/ATP translocase 2 171 40 4 0.4
P61204 ADP-ribosylation factor 3 12 20 2 0.4
H0YN42 Annexin (Fragment) 28 33 8 0.4
P04083 Annexin A1 457 66 21 0.2
P02647 Apolipoprotein A-I 52 53 15 0.2
B7Z7E9 Aspartate aminotransferase 17 16 5 0.3
P00505 Aspartate aminotransferase, mitochondrial 48 18 8 0.5
P48047 ATP synthase subunit 11 27 4 0.5
O43681 ATPase ASNA1 11 7 3 0.4
Q08211 ATP-dependent RNA helicase A 346 34 36 0.5
Q92499 ATP-dependent RNA helicase DDX1 31 14 10 0.5
O95816 BAG family molecular chaperone regulator 2 21 27 6 0.4
P51572 B-cell receptor-associated protein 31 17 13 4 0.4
E9PK09 Bcl-2-associated transcription factor 1 (Fragment) 13 6 5 0.3
P07686 Beta-hexosaminidase subunit beta 30 13 6 0.4
P07814 Bifunctional glutamate/proline–tRNA ligase 39 12 17 0.4
P31327 Carbamoyl-phosphate synthase [ammonia], mitochondrial 22 8 9 0.4
E9PFZ2 Ceruloplasmin 10 4 3 0.3
F5GWX5 Chromodomain-helicase-DNA-binding protein 4 23 3 6 0.4
B4DJV2 Citrate synthase 56 18 3 0.6
F5H669 Cleavage and polyadenylation-specificity factor subunit 7 13 17 6 0.6
Q9NX63 Coiled-coil-helix-coiled-coil-helix domain-containing protein 3 15 15 4 0.4
Q9P0M6 Core histone macro-H2A.2 21 12 2 0.4
H3BSJ9 Cytochrome b-c1 complex subunit 2, mitochondrial 31 33 8 0.4
P47985 Cytochrome b-c1 complex subunit Rieske, mitochondrial 12 13 3 0.4
Q14204 Cytoplasmic dynein 1 heavy chain 1 51 6 23 0.4
Q9Y295 Developmentally-regulated GTP-binding protein 1 13 14 4 0.2
H0Y8E6 DNA replication licensing factor MCM2 (Fragment) 36 11 8 0.3
P33992 DNA replication licensing factor MCM5 28 12 8 0.4
E9PCY5 DNA topoisomerase 2 (Fragment) 61 16 9 0.5
P11388 DNA topoisomerase 2-alpha 89 16 14 0.4
E7EUY0 DNA-dependent protein kinase catalytic subunit 160 11 42 0.4
C9J4M6 DNA-directed RNA polymerase 22 5 6 0.5
B4DX52 DnaJ homolog subfamily B member 1 11 12 3 0.3
P49792 E3 SUM 11 3 8 0.5
Q9HC35 Echinoderm microtubule-associated protein-like 4 13 6 5 0.4
P68104 Elongation factor 1-alpha 1 345 34 6 0.5
E9PK01 Elongation factor 1-delta (Fragment) 15 27 5 0.2
Q9Y371 Endophilin-B1 10 14 5 0.3
P30040 Endoplasmic reticulum resident protein 29 32 38 8 0.5
P30084 Enoyl-CoA hydratase, mitochondrial 12 18 4 0.6
P05198 Eukaryotic translation initiation factor 2 subunit 1 16 15 5 0.2
F5H335 Eukaryotic translation initiation factor 3 subunit A 78 15 18 0.3
Q13347 Eukaryotic translation initiation factor 3 subunit I 11 13 4 0.2
P56537 Eukaryotic translation initiation factor 6 11 30 5 0.3
Q9NPD3 Exosome complex component RRP41 16 15 3 0.4
Q9Y5B9 FACT complex subunit SPT16 21 7 7 0.4
Q08945 FACT complex subunit SSRP1 45 16 12 0.6
P49327 Fatty acid synthase 98 14 28 0.3
P30043 Flavin reductase (NADPH) 11 31 4 0.5
P04075 Fructose-bisphosphatealdolase A 176 57 18 0.2
K7EQ48 Glucose-6-phosphate isomerase 45 16 8 0.5
B4DWJ2 Glutamine–tRNA ligase 17 11 8 0.5
O76003 Glutaredoxin-3 11 12 3 0.2
P78417 Glutathione S-transferase omega-1 28 14 3 0.4
P09211 Glutathione S-transferase P 15 25 4 0.4
P04406 Glyceraldehyde-3-phosphate dehydrogenase 247 55 16 0.2
H3BM42 Golgi apparatus protein 1 10 2 2 0.4
Q08379 Golgin subfamily A member 2 16 6 5 0.4
Q9UIJ7 GTP:AMP phosphotransferase AK3, mitochondrial 12 26 6 0.5
P62826 GTP-binding nuclear protein Ran 15 25 5 0.4
Q5T3Q7 HEAT repeat-containing protein 1 12 3 5 0.6
P07900 Heat shock protein HSP 90-alpha 716 55 24 0.5
P08238 Heat shock protein HSP 90-beta 925 56 24 0.5
D6R9P3 Heterogeneous nuclear ribonucleoprotein A/B 24 18 5 0.4
F8W6I7 Heterogeneous nuclear ribonucleoprotein A1 102 44 10 0.3
G3V4W0 Heterogeneous nuclear ribonucleoproteins C1/C2 (Fragment) 72 41 13 0.4
Q86YZ3 Hornerin 11 4 2 0.4
Q9Y4L1 Hypoxia up-regulated protein 1 182 39 33 0.5
P52292 Importin subunit alpha-1 17 10 6 0.6
Q12905 Interleukin enhancer-binding factor 2 68 22 7 0.5
P50213 Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial 27 26 8 0.3
O75874 Isocitrate dehydrogenase [NADP] cytoplasmic 15 16 6 0.2
B4DFL2 Isocitrate dehydrogenase [NADP] 19 19 6 0.4
Q9P2E9-2 Isoform 1 of Ribosome-binding protein 1 38 20 12 0.4
Q99714-2 Isoform 2 of 3-hydroxyacyl-CoA dehydrogenase type-2 51 54 8 0.5
Q92688-2 Isoform 2 of Acidic leucine-rich nuclear phosphoprotein 32 11 19 2 0.3
P23526-2 Isoform 2 of Adenosylhomocysteinase 13 7 3 0.3
O00571-2 Isoform 2 of ATP-dependent RNA helicase DDX3X 54 24 14 0.6
Q00610-2 Isoform 2 of Clathrin heavy chain 1 230 31 40 0.4
O15160-2 Isoform 2 of DNA-directed RNA polymerases I and III subunit 10 17 4 0.3
P21333-2 Isoform 2 of Filamin-A 385 29 56 0.4
P78347-2 Isoform 2 of General transcription factor II-I 57 13 12 0.5
P51991-2 Isoform 2 of Heterogeneous nuclear ribonucleoprotein A3 39 22 6 0.5
P31942-2 Isoform 2 of Heterogeneous nuclear ribonucleoprotein H3 25 17 4 0.3
Q86UP2-2 Isoform 2 of Kinectin 66 15 17 0.4
Q9NZM1-2 Isoform 2 of Myoferlin 35 7 12 0.5
P12036-2 Isoform 2 of Neurofilament heavy polypeptide 94 8 5 0.4
Q9Y617-2 Isoform 2 of Phosphoserine aminotransferase 14 17 5 0.2
P11940-2 Isoform 2 of Polyadenylate-binding protein 1 70 31 15 0.6
O75400-2 Isoform 2 of Pre-mRNA-processing factor 40 homolog A 19 10 7 0.4
P28370-2 Isoform 2 of Probable global transcription activator SNF2L1 42 9 2 0.4
P25788-2 Isoform 2 of Proteasome subunit alpha type-3 24 24 6 0.3
Q5VT52-2 Regulation of nuclear pre-mRNA domain-containing protein 2 10 5 5 0.5
Q92900-2 Isoform 2 of Regulator of nonsense transcripts 1 18 7 6 0.4
Q5JTH9-2 Isoform 2 of RRP12-like protein 24 8 8 0.5
P16615-2 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 43 15 12 0.5
Q9H2G2-2 Isoform 2 of STE20-like serine/threonine-protein kinase 11 4 5 0.4
A6NHR9-2 Structural maintenance of CFH domain-containing protein 1 15 2 4 0.3
O14776-2 Isoform 2 of Transcription elongation regulator 1 15 4 6 0.4
P60174-1 Isoform 2 of Triosephosphateisomerase 112 62 14 0.3
P07951-2 Isoform 2 of Tropomyosin beta chain 21 20 4 0.2
O43399-2 Isoform 2 of Tumor protein D54 19 31 4 0.4
Q9UIG0-2 Isoform 2 of Tyrosine-protein kinase BAZ1B 33 9 12 0.4
Q9NYU2-2 Isoform 2 of UDP-glucose:glycoproteinglucosyltransferase 1 27 7 8 0.6
P30622-2 Isoform 3 of CAP-Gly domain-containing linker protein 1 16 4 6 0.4
Q9Y281-3 Isoform 3 of Cofilin-2 11 18 2 0.3
P33993-3 Isoform 3 of DNA replication licensing factor MCM7 18 17 7 0.6
Q14103-3 Isoform 3 of Heterogeneous nuclear ribonucleoprotein D0 23 27 7 0.4
P06756-3 Isoform 3 of Integrin alpha-V 111 25 23 0.5
Q7L2E3-3 Isoform 3 of Putative ATP-dependent RNA helicase DHX30 22 8 8 0.4
P08559-3 Pyruvate dehydrogenase E1 component subunit alpha, 18 14 5 0.4
Q13813-3 Isoform 3 of Spectrin alpha chain, non-erythrocytic 1 135 16 34 0.4
Q99832-3 Isoform 3 of T-complex protein 1 subunit eta 75 36 14 0.5
Q86W42-3 Isoform 3 of TH 11 24 5 0.3
Q14669-4 Isoform 4 of E3 ubiquitin-protein ligase TRIP12 18 4 5 0.4
Q8N766-4 Isoform 4 of ER membrane protein complex subunit 1 14 5 3 0.5
P54819-5 Isoform 5 of Adenylate kinase 2, mitochondrial 16 30 5 0.3
O75369-6 Isoform 6 of Filamin-B 48 5 8 0.5
P27816-6 Isoform 6 of Microtubule-associated protein 4 25 10 10 0.4
Q04637-7 Isoform 7 of Eukaryotic translation initiation factor 4 gamma 1 29 8 11 0.3
Q15149-7 Isoform 7 of Plectin 99 9 34 0.4
Q00325-2 Isoform B of Phosphate carrier protein, mitochondrial 40 15 6 0.4
P02788-2 Isoform DeltaLf of Lactotransferrin 22 8 5 0.4
P31946-2 Isoform Short of 14–3-3 protein beta/alpha 48 36 3 0.3
P46013-2 Isoform Short of Antigen KI-67 20 4 8 0.5
O75534-2 Isoform Short of Cold shock domain-containing protein E1 11 9 6 0.6
Q15056-2 Isoform Short of Eukaryotic translation initiation factor 4H 10 29 5 0.3
J3KR24 Isoleucine–tRNA ligase, cytoplasmic 25 6 7 0.3
P42704 Leucine-rich PPR motif-containing protein, mitochondrial 334 32 43 0.5
P00338 l-lactate dehydrogenase A chain 15 9 2 0.4
P07195 l-lactate dehydrogenase B chain 14 9 2 0.5
O00264 Membrane-associated progesterone receptor component 1 17 16 3 0.6
B4E1E9 Mitochondrial dicarboxylate carrier 12 19 5 0.5
Q9BQG0 Myb-binding protein 1A 60 15 18 0.5
P19105 Myosin regulatory light chain 12A 13 19 3 0.5
P35580 Myosin-10 36 5 3 0.4
P35579 Myosin-9 163 20 28 0.4
O75489 NADH dehydrogenase [ubiquinone] iron-sulfur protein 3 26 33 7 0.5
P48681 Nestin 40 9 13 0.4
Q09666 Neuroblast differentiation-associated protein AHNAK 17 5 7 0.4
P69849 Nodal modulator 3 25 9 9 0.5
Q14980 Nuclear mitotic apparatus protein 1 130 22 39 0.6
P49790 Nuclear pore complex protein Nup153 16 6 7 0.6
E9PF10 Nuclear pore complex protein Nup155 14 5 6 0.6
Q92621 Nuclear pore complex protein Nup205 20 4 9 0.5
Q8TEM1 Nuclear pore membrane glycoprotein 210 21 6 8 0.5
Q14978 Nucleolar and coiled-body phosphoprotein 1 28 17 10 0.5
P06748 Nucleophosmin 113 46 13 0.3
P12270 Nucleoprotein TPR 82 12 28 0.6
Q02790 Peptidyl-prolylcis-trans isomerase FKBP4 36 25 10 0.5
P32119 Peroxiredoxin-2 45 26 5 0.5
H7C3T4 Peroxiredoxin-4 (Fragment) 36 39 4 0.5
P30041 Peroxiredoxin-6 49 24 6 0.3
O95571 Persulfidedioxygenase ETHE1, mitochondrial 12 16 3 0.4
P00558 Phosphoglycerate kinase 1 37 30 10 0.2
P18669 Phosphoglyceratemutase 1 71 43 9 0.3
E9PBS1 Phosphoribosylaminoimidazole carboxylase (Fragment) 10 9 3 0.4
O15067 Phosphoribosylformylglycinamidine synthase 10 6 5 0.3
Q15102 Platelet-activating factor acetylhydrolase IB subunit gamma 24 22 5 0.3
Q15365 Poly(rC)-binding protein 1 35 28 4 0.2
H3BRU6 Poly(rC)-binding protein 2 (Fragment) 33 30 4 0.3
O75915 PRA1 family protein 3 13 16 2 0.4
Q6P2Q9 Pre-mRNA-processing-splicing factor 8 61 11 21 0.4
Q8IY81 pre-rRNA processing protein FTSJ3 19 8 7 0.4
P07737 Profilin-1 95 65 9 0.4
P25789 Proteasome subunit alpha type-4 14 16 5 0.3
P28066 Proteasome subunit alpha type-5 18 23 4 0.3
P60900 Proteasome subunit alpha type-6 42 35 9 0.2
P20618 Proteasome subunit beta type-1 17 17 4 0.4
J3KSM3 Proteasome subunit beta type-3 15 23 2 0.4
P28070 Proteasome subunit beta type-4 20 19 4 0.2
P28074 Proteasome subunit beta type-5 11 17 4 0.5
P28072 Proteasome subunit beta type-6 19 13 3 0.4
Q99436 Proteasome subunit beta type-7 11 18 4 0.3
Q14690 Protein RRP5 homolog 12 3 5 0.5
Q99584 Protein S100-A13 23 48 5 0.6
P05109 Protein S100-A8 11 40 4 0.6
P06702 Protein S100-A9 22 38 4 0.4
P14618 Pyruvate kinase PKM 371 64 32 0.7
P46940 RasGTPase-activating-like protein IQGAP1 65 13 18 0.5
Q15907 Ras-related protein Rab-11B 48 39 9 0.6
P61106 Ras-related protein Rab-14 26 25 4 0.3
P62820 Ras-related protein Rab-1A 37 36 6 0.5
B4DJA5 Ras-related protein Rab-5A 13 21 2 0.4
P51148 Ras-related protein Rab-5C 26 19 2 0.3
J3QR09 Ribosomal protein L19 16 21 4 0.1
P38159 RNA-binding motif protein, X chromosome 61 44 17 0.6
P49756 RNA-binding protein 25 11 7 4 0.4
Q5QPM1 RNA-binding protein Raly (Fragment) 16 27 5 0.5
Q14151 Scaffold attachment factor B2 18 4 2 0.5
P35270 Sepiapterin reductase 14 33 6 0.4
B5MCX3 Septin-2 15 25 6 0.2
B4E241 Serine/arginine-rich-splicing factor 3 21 25 3 0.6
P62136 Serine/threonine-protein phosphatase PP1-alpha catalytic 21 25 3 0.3
P02768 Serum albumin 123 43 25 0.4
Q9Y5M8 Signal recognition particle receptor subunit beta 11 14 3 0.4
J3QLE5 Small nuclear ribonucleoprotein-associated protein N 21 26 4 0.3
Q01082 Spectrin beta chain, non-erythrocytic 1 62 10 21 0.5
O75533 Splicing factor 3B subunit 1 93 19 21 0.4
Q13435 Splicing factor 3B subunit 2 40 10 8 0.6
Q15393 Splicing factor 3B subunit 3 56 10 10 0.5
B4E1K7 Stomatin-like protein 2, mitochondrial 36 32 7 0.5
Q14683 Structural maintenance of chromosomes protein 1A 20 5 7 0.4
Q9UQE7 Structural maintenance of chromosomes protein 3 12 5 5 0.4
Q6UWP8 Suprabasin 17 15 2 0.4
O60264 SWI/SNF-related matrix-associated actin-dependent regulator 73 16 9 0.5
Q92797 Symplekin 11 4 4 0.5
Q5TCU6 Talin-1 39 6 12 0.4
P17987 T-complex protein 1 subunit alpha 85 40 19 0.6
P40227 T-complex protein 1 subunit zeta 97 33 15 0.5
Q9BRA2 Thioredoxin domain-containing protein 17 17 33 4 0.5
E9PH29 Thioredoxin-dependent peroxide reductase, mitochondrial 73 26 6 0.6
Q8NI27 TH 14 5 8 0.4
Q9Y2W1 Thyroid hormone receptor-associated protein 3 35 13 10 0.3
P37837 Transaldolase 19 13 5 0.3
Q01995 Transgelin 13 35 6 0.4
P37802 Transgelin-2 15 23 4 0.5
Q92616 Translational activator GCN1 31 5 11 0.4
P09661 U2 small nuclear ribonucleoprotein A' 26 31 7 0.5
P08579 U2 small nuclear ribonucleoprotein B'' 17 24 5 0.4
O75643 U5 small nuclear ribonucleoprotein 200 kDa helicase 67 10 18 0.5
P09936 Ubiquitin carboxyl-terminal hydrolase isozyme L1 22 26 6 0.3
D6RDM7 Ubiquitin-conjugating enzyme E2 K (Fragment) 13 22 2 0.5
P54727 UV excision repair protein RAD23 homolog B 18 18 7 0.5
P26640 Valine–tRNA ligase 13 4 4 0.4
O75396 Vesicle-trafficking protein SEC22b 15 15 3 0.4
Q00341 Vigilin 25 8 8 0.4
P08670 Vimentin 1987 81 43 0.4
P13010 X-ray repair cross-complementing protein 5 58 17 11 0.6
Fig. 4.

Fig. 4.

MS/MS spectra for identification of Rab 5C: A MS/MS spectrum of a doubly charged TMT-labeled peptide ion at m/z 764. 9025 for MH22+ corresponding to the mass of the peptide GVDLQENNPASR from Rab 5C. Fig. inserts show peaks of TMT reporter ions of two labeled peptides.

Fig. 5.

Fig. 5.

Confirmation of differentially expressed proteins by Western and qPCR. A, Western blot analysis of selected proteins from A2780 and A2780-DR cells. B, qPCR analysis of selected genes from A2780 and A2780-DR cells. ** for p value <0.001; and *** for p value <0.001.

Rab 5C Mediated Cisplatin-resistance

To understand the role of Rab 5C and Rab 11B in drug-resistance, shRNAs were used to silence Rab 5C and Rab 11B in A2780 cells. The plasmid NCi-pll3.7 was also transfected into A2780 as the control to exclude effects of cytotoxicity caused by transfection. The silencing of Rab 5C and Rab 11B was verified by Western blotting and qPCR assays (supplemental Fig. S1). The expression level of Rab 5C mRNA decreased to 30% of that observed for NCi-pll3.7 -transfected cells, whereas the expression level of Rab 11B mRNA decreased to 57% of the control. The sensitivities of shRNA-transfected cells to cisplatin were analyzed by CCK8 assay after cells were treated with different concentrations of cisplatin for 24 h. When cells were treated with 40 μm cisplatin for 24 h, differences in sensitivity to cisplatin were observed among NCi-pll3.7- and Rab 5C shRNA-transfected cells. The change of drug resistance in Rab 11B shRNA-transfected cells is less significant as compared with A2780 cells. Results demonstrate that transfection of A2780 cells with shRNA against Rab 5C increases cell resistance to cisplatin. The IC50 and resistance index values of shRNA-transfected cell lines are 103.3 and 1.89 for Rab 5C, and 62.7 and 1.39 for Rab 11B (Table I).

To further explore Rab 5C mediated drug resistance, Rab 5C was sub-cloned into eukaryotic plasmid pcDNA3.1 that was transfected into A2780-DR cells. The overexpression of Rab 5C in A2780 cells was examined by Western blotting (supplemental Fig. S1C), showing that the expression level of Rab 5C in A2780-DR cells is three times higher than that in empty vector-transfected cells. The sensitivities of Rab 5C overexpressing cells to cisplatin were analyzed by CCK8 assay after cells were treated with different concentrations of cisplatin for 24 h (Fig. 6C), demonstrating that overexpression of Rab 5C in A2780-DR cells increases cell susceptibility to cisplatin.

Fig. 6.

Fig. 6.

Cell cytotoxicity assays. Percentage of viable A2780, shRNA-transfected A2780, and Rab 5C-pcDNA3.1-transfected cells treated with cisplatin at different concentrations for 24 h determined by using CCK-8 assay. Results are expressed as the mean of three experiments; A, Rab 5Ci; B, Rab 11Bi; and C, Rab 5C-pcDNA3.1. ***p < 0.001.

DISCUSSION

Multidrug resistance is the main reason for the failure of ovarian cancer chemotherapy. The establishment of drug resistant cancer cell lines is an important step in providing an in vitro model for understanding the mechanism of drug resistance and for identifying new therapeutic targets. Cisplatin is a traditional anticancer drug used in clinical settings. In this study, we used human ovarian cell line A2780 as a model system to establish a cisplatin resistant cell line A2780-DR. By the stepwise increase of cisplatin concentration in the growth medium and selection of drug-resistance colonies for six months, we successfully established a cisplatin-resistant cell line with the resistance index 6.76. Using mass spectrometry analysis, it was found that Pt accumulation in A2780-DR cells was only one third of that in A2780 cells, suggesting that a reduction in cellular Pt accumulation is the major cause of drug-resistance in A2780-DR cells.

To identify factors leading to drug resistance, we used TMT labeling to quantify proteins from two types of cells. TMT-labeling uses an isobaric tag with an amine-reactive NHS-ester group, which enables quantitation of two samples with a single LC-MS/MS run that eliminates experimental variation. It also enhances the ionization efficiency of peptides to make them more amenable for MS analysis. We identified about 1900 proteins in three repeated experiments. Among them, 340 proteins were differentially expressed between A2780 and A2780-DR cells, which participate in a variety of cellular processes including cell metabolism, stress responses, cell cycle, and DNA repair. Based on GO analysis, 135 proteins are associated with the metabolic processes including ferredoxin metabolic process (GO:0006124); nitrogen compound metabolic process (GO:0006807); oxygen and reactive oxygen species metabolic process (GO:0006800); phosphate metabolic process (GO:0006796); and primary metabolic process (GO:0044238).

Five out of ten glycolytic proteins were down-regulated including Glucose-6-phosphate isomerase (GPI), fructose-bisphosphate aldolase (ALDO), lactate dehydrogenase (LDH), PGK, and pyruvate kinase (PKM), indicating that glycolysis was down-regulated in drug-resistant cells. This is consistent with an earlier report showing that ALDO and PGK are down-regulated in drug-resistant cells (32). The other proteomic study has also linked the decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer, showing tumors with the lowest PKM2 levels attain the lowest oxaliplatin response rates and the high PKM2 levels are associated with high p53 levels (44). In the present study, the expression level of PKM in A2780-DR cells was about half of that in A2780 cells (Table III) by quantitative proteomic analysis. This was confirmed by Western blotting (Fig. 5). The mRNA level of PKM2 in A2780-DR cells was also down-regulated compared with A2780 cells by qPCR analysis. PKM2 catalyzes the rate-limiting step of glycolysis, in which phosphoenolpyruvate is converted to pyruvate. As a key enzyme for cancer metabolism and tumor growth, PKM2 and other glycolytic enzymes were found to be up-regulated in most cancer cells (4547). However, our results and previous studies have shown that down-regulation of glycolytic enzymes are a characteristic of drug-resistant ovarian cancer and colorectal cancer cells (32, 44). Although the molecular events leading to down-regulation of glycolytic enzymes are still not clear, we have found that expression levels of c-Myc and HIF1A are down-regulated in drug-resistant cells. Western blots of c-Myc and HIF1A are displayed in supplemental Fig. S2, showing that both c-Myc and HIF1a are down-regulated in A2780-DR cells. c-Myc is an oncogene that regulates transcription of many growth related genes. HIF1A is a master transcriptional regulator of the adaptive response to hypoxia that activates the transcription of glycolytic enzymes. Down-regulation of c-Myc and HIF1A results in decreases in expression levels of glycolytic enzymes that may contribute to drug resistance in ovarian cancer cells.

Cisplatin is a potent electrophile covalently modifying nucleophilic sites on proteins, lipids, DNA, and RNA to generate reactive oxygen species and to induce cell apoptosis. To explore the difference in endogenous ROS levels between A280 and A2780-DR, the intracellular ROS levels were measured with the Image-iT™ LIVE Green Reactive Oxygen Species Detection Kit in both cells. Results show that the ROS level in A2780-DR cells is lower than that in A2780 cells (supplemental Fig. S3), indicating that A2780_DR cells possess a higher capacity to accommodate cisplatin-induced ROS stress. However, quantitative proteomics showed that some redox proteins such as peroxiredoxin-6 (PRDX6) and thioredoxin reductase 1 (TR1) were down-regulated, whereas glutathione reductase (GSR) is up-regulated in A2780-DR cells (Table II). GSR maintains high levels of reduced glutathione in the cytosol, and the up-regulation of GSR may lead to a decrease of ROS in A2780-DR cells. Studies are underway to understand the complex interactions of ROS and the cellular antioxidant system.

On 1D SDS-PAGE (Fig. 2), band 7 has the largest change in intensity, in which vimentin was identified as the major protein. Quantitative proteomics showed that expression of vimentin was decreased 2-fold in A2780-DR cells as compared with A2780 cells, which was confirmed by Western blotting (Fig. 5A). Vimentin is a major intermediate filament protein and is ubiquitously expressed to maintain cellular integrity. Overexpression of vimentin has been observed in various epithelial cancers and correlated with accelerated tumor growth, invasion, and poor prognosis (50). Furthermore, etoposide resistance in neuroblastoma cell and vinca alkaloid resistance in acute lymphoblastic leukemia have been linked to overexpression of vimentin (5152). However, down-regulation of vimentin has been found in resistant1A9 cells to the microtubule stabilizing agents, PLA and LAU (53), consistent with results from the present study. Therefore, changes in expression levels of vimentin are cancer-type dependent and vimentin is a potential marker for drug-resistance in ovarian cancer.

Decreased cellular drug accumulation is the most commonly observed phenomenon among drug resistant cells. In the present study, we found that cisplatin accumulation was lower in drug-resistant cells (Fig. 1). It is known that cisplatin was not a substrate of P-glycoprotein the key mediator for drug efflux (1013). Therefore, reduction of cisplatin accumulation in drug-resistant cells may be related to uptake of cisplatin. Uptake of cisplatin can be governed by different mechanisms including passive diffusion, carrier-mediated transporting, and endocytosis (54). An elegant study has shown that several small GTPases (Rab 5, Rac 1, and Rho A) were down-regulated in cisplatin-resistant human hepatoma and epidermal carcinoma cells, demonstrating that GTPase-regulated endocytosis is an important factor in drug-resistance (55). Quantitative proteomic analysis in this study shows that Ras-related proteins Rab 5C and Rab 11B are down-regulated in A2780-DR cells as confirmed by Western blotting and qPCR. Rab 5C is a member of the Rab protein family and a key regulator in endocytosis and early endosome fusion, whereas Rab 11 has been associated with endosome recycling (56). Therefore, down-regulation of Rab 5C and Rab 11B may result in reduced accumulation of cisplatin. To further confirm Rab 5C and Rab 11B mediated drug-resistance, shRNAs against Rab 5C and Rab 11B were used to silence these genes in A2780 cells. As predicted, silencing Rab 5C in A2780 cells lead to increased drug resistance (Fig. 6), but effects of Rab 11B shRNA are less significant (Table I). On the other hand, overexpression of Rab5C in A2780-DR cells increases its sensitivity to cisplatin treatment. These results suggest for the first time that Rab 5C mediated endocytosis regulates drug resistance in ovarian cancer cells.

CONCLUSIONS

Taken together, our results show that multiple cellular processes contribute to drug resistance in ovarian cancer cells. Although increased glycolysis is observed in most cancer cells, glycolytic enzymes PKM2, GPI, ALDO, LDH, and PGK are down-regulated in drug-resistant ovarian cancer cells. Drug resistance is also associated with a decrease of the endogenous ROS level, the up-regulation of GSR, as well as down-regulation of vimentin. Furthermore, the down-regulation of Rab 5C-mediated endocytosis contributes to the reduction of cellular cisplatin accumulation and drug-resistance. These results further our understanding of the multifactorial mechanisms in acquisition and development of cisplatin resistance in human cancer cells.

Supplementary Material

Supplemental Data

Acknowledgments

We thank the Protein Chemistry Facility at the Center for Biomedical Analysis of Tsinghua University for sample analysis. We thank Dr Zhenyu Zhang for valuable discussions.

Footnotes

Author contributions: Q.L., R.G., and Haiteng Deng designed research; L.J., Y.H., Z.Z., X.J., and Haiyun Deng performed research; L.J., Y.H., Z.Z., Y.C., and Haiteng Deng analyzed data; Haiteng Deng wrote the paper.

* This work was supported in part by NSFC 30871434 (R.S.G.) and NSFC 31270871 (H.T.D), the Chinese Ministry of Science and Technology 2014CBA02005 (H.T.D) and the Global Science Alliance Program of Thermo-Fisher Scientific.

1 The abbreviations used are:

PGP
phosphoglycerate kinase
ROS
reactive oxygen species
GO
Gene Ontology
PKM
pyruvate kinase.

REFERENCES

  • 1. Bell D., Berchuck A., Birrer M., Chien J., Cramer D., Dao F., Dhir R., Disaia P., Gabra H., Glenn P. (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474, 609–615 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Miller D. S., Blessing J. A., Krasner C. N., Mannel R. S., Hanjani P., Pearl M. L., Waggoner S. E., Boardman C. H. (2009) Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J. Clin. Oncol. 27, 2686–2691 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M. J. (2009) Cancer statistics, 2009. CA Cancer J. Clin. 59, 225–249 [DOI] [PubMed] [Google Scholar]
  • 4. Fojo A., Hamilton T. C., Young R. C., Ozols R. F. (1987) Multidrug resistance in ovarian cancer. Cancer 60, 2075–2080 [DOI] [PubMed] [Google Scholar]
  • 5. Safaei R., Howell S. B. (2005) Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit. Rev. Oncol. Hemat. 53, 13–23 [DOI] [PubMed] [Google Scholar]
  • 6. Ishida S., Lee J., Thiele D. J., Herskowitz I. (2002) Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc. Natl. Acad. Sci. 99, 14298–14302 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Safaei R., Katano K., Samimi G., Naerdemann W., Stevenson J. L., Rochdi M., Howell S. B. (2004) Cross-resistance to cisplatin in cells with acquired resistance to copper. Cancer Chemoth. Pharm. 53, 239–246 [DOI] [PubMed] [Google Scholar]
  • 8. Lin X., Okuda T., Holzer A., Howell S. B. (2002) The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol. Pharmacol. 62, 1154–1159 [DOI] [PubMed] [Google Scholar]
  • 9. Holzer A. K., Katano K., Klomp L. W., Howell S. B. (2004) Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells. Clin. Cancer Res. 10, 6744–6749 [DOI] [PubMed] [Google Scholar]
  • 10. Breier A., Gibalova L., Seres M., Barancik M., Sulova Z. (2013) New Insight into P-glycoprotein as a drug target. Anti-Cancer Agent. Me. 13, 159–170 [PubMed] [Google Scholar]
  • 11. Cocker H. A., Tiffin N., Pritchard-Jones K., Pinkerton C. R., Kelland L. R. (2001) In vitro prevention of the emergence of multidrug resistance in a pediatric rhabdomyosarcoma cell line. Clin. Cancer Res. 7, 3193–3198 [PubMed] [Google Scholar]
  • 12. Yang X., Page M. (1995) P-glycoprotein expression in ovarian cancer cell line following treatment with cisplatin. Oncol. Res. 7, 619–624 [PubMed] [Google Scholar]
  • 13. Stordal B., Hamon M., McEneaney V., Roche S., Gillet J.-P., O'Leary J. J., Gottesman M., Clynes M. (2012) Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein. PLoS One 7, e40717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Kelland L. (2007) The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 7, 573–584 [DOI] [PubMed] [Google Scholar]
  • 15. Sakamoto M., Kondo A., Kawasaki K., Goto T., Sakamoto H., Miyake K., Koyamatsu Y., Akiya T., Iwabuchi H., Muroya T. (2001) Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray. Human Cell 14, 305–315 [PubMed] [Google Scholar]
  • 16. Li M., Balch C., Montgomery J. S., Jeong M., Chung J. H., Yan P., Huang T. H., Kim S., Nephew K. P. (2009) Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med. Genomics 2, 34. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Godwin A. K., Meister A., O'Dwyer P. J., Huang C. S., Hamilton T. C., Anderson M. E. (1992) High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc. Natl. Acad. Sci. 89, 3070–3074 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Hector S., Nava M. E., Clark K., Murphy M., Pendyala L. (2007) Characterization of a clonal isolate of an oxaliplatin resistant ovarian carcinoma cell line A2780/C10. Cancer Lett. 245, 195–204 [DOI] [PubMed] [Google Scholar]
  • 19. Martin L. P., Hamilton T. C., Schilder R. J. (2008) Platinum resistance: the role of DNA repair pathways. Clin. Cancer Res. 14, 1291–1295 [DOI] [PubMed] [Google Scholar]
  • 20. Selvakumaran M., Pisarcik D. A., Bao R., Yeung A. T., Hamilton T. C. (2003) Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res. 63, 1311–1316 [PubMed] [Google Scholar]
  • 21. Dabholkar M., Vionnet J., Bostick-Bruton F., Yu J. J., Reed E. (1994) Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J. Clin. Invest. 94, 703–708 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Kohn E. C., Sarosy G., Bicher A., Link C., Christian M., Steinberg S. M., Rothenberg M., Adamo D. O., Davis P., Ognibene F. P. (1994) Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J. Natl. Cancer I. 86, 18–24 [DOI] [PubMed] [Google Scholar]
  • 23. Murphy M. A., Wentzensen N. (2011) Frequency of mismatch repair deficiency in ovarian cancer: a systematic review. Int. J. Cancer 129, 1914–1922 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Sakai W., Swisher E. M., Karlan B. Y., Agarwal M. K., Higgins J., Friedman C., Villegas E., Jacquemont C., Farrugia D. J., Couch F. J. (2008) Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451, 1116–1120 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Edwards S. L., Brough R., Lord C. J., Natrajan R., Vatcheva R., Levine D. A., Boyd J., Reis-Filho J. S., Ashworth A. (2008) Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451, 1111–1115 [DOI] [PubMed] [Google Scholar]
  • 26. Swisher E. M., Sakai W., Karlan B. Y., Wurz K., Urban N., Taniguchi T. (2008) Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 68, 2581–2586 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Ali A. Y., Farrand L., Kim J. Y., Byun S., Suh J. Y., Lee H. J., Tsang B. K. (2012) Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum. Ann. NY Acad. Sci. 1271, 58–67 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Stronach E. A., Chen M., Maginn E. N., Agarwal R., Mills G. B., Wasan H., Gabra H. (2011) DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance. Neoplasia 13, 1069–1080 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Stronach E. A., Alfraidi A., Rama N., Datler C., Studd J. B., Agarwal R., Guney T. G., Gourley C., Hennessy B. T., Mills G. B. (2011) HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. Cancer Res. 71, 4412–4422 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Yan X., Pan L., Yuan Y., Lang J., Mao N. (2007) Identification of platinum-resistance associated proteins through proteomic analysis of human ovarian cancer cells and their platinum-resistant sublines. J. Proteome Res. 6, 772–780 [DOI] [PubMed] [Google Scholar]
  • 31. Jinawath N., Vasoontara C., Jinawath A., Fang X., Zhao K., Yap K.-L., Guo T., Lee C. S., Wang W., Balgley B. M. (2010) Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma. PLoS One 5, e11198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Gong F., Peng X., Zeng Z., Yu M., Zhao Y., Tong A. (2011) Proteomic analysis of cisplatin resistance in human ovarian cancer using 2-DE method. Mol. Cell. Biochem. 348, 141–147 [DOI] [PubMed] [Google Scholar]
  • 33. Di Michele M., Della Corte A., Cicchillitti L., Del Boccio P., Urbani A., Ferlini C., Scambia G., Donati M. B., Rotilio D. (2009) A proteomic approach to paclitaxel chemoresistance in ovarian cancer cell lines. Biochim. Biophys. Acta 1794, 225–236 [DOI] [PubMed] [Google Scholar]
  • 34. Stewart J. J., White J. T., Yan X., Collins S., Drescher C. W., Urban N. D., Hood L., Lin B. (2006) Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. Mol. Cell. Proteomics 5, 433–443 [DOI] [PubMed] [Google Scholar]
  • 35. Cicchillitti L., Di Michele M., Urbani A., Ferlini C., Donati M. B., Scambia G., Rotilio D. (2009) Comparative proteomic analysis of paclitaxel sensitive A2780 epithelial ovarian cancer cell line and its resistant counterpart A2780TC1 by 2D-DIGE: the role of ERp57. J. Proteome Res. 8, 1902–1912 [DOI] [PubMed] [Google Scholar]
  • 36. Yang Z., Schumaker L. M., Egorin M. J., Zuhowski E. G., Guo Z., Cullen K. J. (2006) Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis. Clin. Cancer Res. 12, 5817–5825 [DOI] [PubMed] [Google Scholar]
  • 37. Custódio J., Cardoso C. M., Santos M. S., Almeida L. M., Vicente J. A., Fernandes M. A. (2009) Cisplatin impairs rat liver mitochondrial functions by inducing changes on membrane ion permeability: prevention by thiol group protecting agents. Toxicology 259, 18–24 [DOI] [PubMed] [Google Scholar]
  • 38. Saitou M., Isonishi S., Hamada T., Kiyokawa T., Tachibana T., Ishikawa H., Yasuda M. (2009) Mitochondrial ultrastructure-associated chemotherapy response in ovarian cancer. Oncology Reports 21, 199–204 [PubMed] [Google Scholar]
  • 39. Liang X., Finkel T., Shen D., Yin J., Aszalos A., Gottesman M. M. (2008) SIRT1 contributes in part to cisplatin resistance in cancer cells by altering mitochondrial metabolism. Mol. Cancer Res, 6, 1499–1506 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Andrews P. A., Albright K. D. (1992) Mitochondrial defects in cis-diamminedichloroplatinum (II)-resistant human ovarian carcinoma cells. Cancer Res. 52, 1895–1901 [PubMed] [Google Scholar]
  • 41. Dai Z., Yin J., He H., Li W., Hou C., Qian X., Mao N., Pan L. (2010) Mitochondrial comparative proteomics of human ovarian cancer cells and their platinum-resistant sublines. Proteomics 10, 3789–3799 [DOI] [PubMed] [Google Scholar]
  • 42. Chappell N. P., Teng P.-n., Hood B. L., Wang G., Darcy K. M., Hamilton C. A., Maxwell G. L., Conrads T. P. (2012) Mitochondrial proteomic analysis of cisplatin resistance in ovarian cancer. J. Proteome Res. 11, 4605–4614 [DOI] [PubMed] [Google Scholar]
  • 43. Minakata K., Nozawa H., Okamoto N., Suzuki O. (2006) Determination of platinum derived from cisplatin in human tissues using electrospray ionization mass spectrometry. J. Chromatogr. B 832, 286–291 [DOI] [PubMed] [Google Scholar]
  • 44. Martinez-Balibrea E., Plasencia C., Ginés A., Martinez-Cardús A., Musulén E., Aguilera R., Manzano J. L., Neamati N., Abad A. (2009) A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines. Mol. Cancer Ther. 8, 771–778 [DOI] [PubMed] [Google Scholar]
  • 45. Christofk H. R., Vander Heiden M. G., Harris M. H., Ramanathan A., Gerszten R. E., Wei R., Fleming M. D., Schreiber S. L., Cantley L. C. (2008) The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452, 230–233 [DOI] [PubMed] [Google Scholar]
  • 46. Mazurek S. (2012) Pyruvate kinase M2: a key enzyme of the tumor metabolome and its medical relevance. Biomedical Res. 23, 133–141 [Google Scholar]
  • 47. Xu R., Pelicano H., Zhou Y., Carew J. S., Feng L., Bhalla K. N., Keating M. J., Huang P. (2005) Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res. 65, 613–621 [PubMed] [Google Scholar]
  • 48. Chung Y., Yoo Y., Park J., Kim Y., Kim H. J. (2000) Increased expression of peroxiredoxin II confers resistance to cisplatin. Anticancer Res. 21, 1129–1133 [PubMed] [Google Scholar]
  • 49. Pak J. H., Choi W. H., Lee H. M., Joo W.-D., Kim J.-H., Kim Y.-T., Kim Y.-M., Nam J.-H. (2011) Peroxiredoxin 6 overexpression attenuates cisplatin-induced apoptosis in human ovarian cancer cells. Cancer Invest. 29, 21–28 [DOI] [PubMed] [Google Scholar]
  • 50. Satelli A., Li S. (2011) Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell. Mol. Life Sci. 68, 3033–3046 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51. Verrills N. M., Walsh B. J., Cobon G. S., Hains P. G., Kavallaris M. (2003) Proteome analysis of vinca alkaloid response and resistance in acute lymphoblastic leukemia reveals novel cytoskeletal alterations. J. Biol. Chem. 278, 45082–45093 [DOI] [PubMed] [Google Scholar]
  • 52. Urbani A., Poland J., Bernardini S., Bellincampi L., Biroccio A., Schnölzer M., Sinha P., Federici G. (2005) A proteomic investigation into etoposide chemo-resistance of neuroblastoma cell lines. Proteomics 5, 796–804 [DOI] [PubMed] [Google Scholar]
  • 53. Kanakkanthara A., Rawson P., Northcote P. T., Miller J. H. (2012) Acquired resistance to Peloruside A and laulimalide is associated with down-regulation of vimentin in human ovarian carcinoma cells. Pharm. Res. 29, 3022–3032 [DOI] [PubMed] [Google Scholar]
  • 54. Arnesano F., Natile G. (2009) Mechanistic insight into the cellular uptake and processing of cisplatin 30 years after its approval by FDA. Coordin. Chem. Rev. 253, 2070–2081 [Google Scholar]
  • 55. Shen D., Su A., Liang X., Pai-Panandiker A., Gottesman M. (2004) Reduced expression of small GTPases and hypermethylation of the folate binding protein gene in cisplatin-resistant cells. Br. J. Cancer 91, 270–276 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56. Schwartz S. L., Cao C., Pylypenko O., Rak A., Wandinger-Ness A. (2007) Rab GTPases at a glance. J. Cell Sci. 120, 3905–3910 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplemental Data

Articles from Molecular & Cellular Proteomics : MCP are provided here courtesy of American Society for Biochemistry and Molecular Biology

RESOURCES